

Suppl. Figure 5

Supplemental Figure 5. p16+ senescent CAFs are preferentially eliminated from MMTV-PyMT/INK+ mice and by senolytics. (A) Representative IHC images of p16 in INK- and INK+ tumor sections from 10 weeks old mice treated with AP20187. **(B)** Quantification of p16 IHC in the tumor versus stromal regions from 10-week-old INK- and INK+ mice (n=4 for each group; *p<0.05; ns, not significant). **(C)** Flow cytometric analyses of vCAF (left) and iCAF (right) from 7-week-old INK- and INK+ mice represented as a percent of total CAF cells (n=8 for each group; *p<0.05; ns, not significant). **(D)** Representative IHC images of p16 in MMTV-PyMT tumor sections from 7-week-old mice treated with Veh or ABT737. **(E)** Quantification of p16 IHC in the tumor versus stromal regions from Veh versus ABT3737 treated mice (n=6 for each group). **(F)** Flow cytometric analyses of vCAF (left) and iCAF (right) from 7-week-old mice treated with Veh (n=9) or ABT737 (n=10) represented as a percent of total CAF cells (n=8 for each group; *p<0.05; ns, not significant). All statistical analyses were conducted using unpaired one-tailed student t-test; data are represented as mean ± SEM.